The gold standard AJCC staging system considers biomarker testing with the hormone receptors ER, PR, and HER2 status, plus integration of Ki‐67 in the determination of the prognostic stage for breast cancer patients [29]. This evidence concerns the gene ESR1 and breast cancer.